The following is a summary of the Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Protalix BioTherapeutics reported Q2 2024 revenues of $13.3 million, a decrease of 12% year-over-year, primarily due to a decrease in sales to Chiesi.

• Net loss for Q2 2024 was approximately $2.2 million, in contrast to a net income of $19.3 million in Q2 2023.

• Recorded a tax benefit of approximately $0.1 million in Q2 2024, contrasting with income taxes of $0.3 million in Q2 2023.

• The company's strong cash position will enable the repayment of convertible notes due in September 2024.

Business Progress:

• Successful continuation of PRX-115's clinical development, with plans to initiate a Phase 2 study.

• Expansion of the PRX-115 Phase 1 study to include an eighth cohort to analyze a higher dose.

• Developmental progression of PRX-119 for diseases associated with neutrophil extracellular traps.

• Ongoing efforts to identify assets for targeting renal rare disease indications using the ProCellEx platform.

Opportunities:

• Protalix's strategic partnership with Chiesi Global Rare Diseases aims for deeper market penetration and development of a Fabry disease franchise.

• Potential market expansion through the development of novel plant-based drug delivery systems.

Risks:

• Payer adoption and market penetration rates may impact the financial outcomes more significantly going forward.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.